cytomx is an oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its probody technology platform. the company uses the platform to create development-stage proprietary cancer immunotherapies against clinically-validated targets, as well as to develop first-in-class investigational cancer therapeutics against novel targets. cytomx believes that its probody platform has the potential to improve the combined efficacy and safety profile of monoclonal antibody modalities, including cancer immunotherapies, antibody drug conjugates and t-cell-recruiting bispecific antibodies. probody therapeutics are designed to take advantage of unique conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues. investigational probody therapeutics are being developed that address clinically-validated cancer targets in immuno-oncology, such as pd-l1 against which o
Company profile
Ticker
CTMX
Exchange
Website
CEO
Sean McCarthy
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
CTMX stock data
Latest filings (excl ownership)
DEFA14A
Additional proxy soliciting materials
4 Apr 24
DEF 14A
Definitive proxy
4 Apr 24
PRE 14A
Preliminary proxy
25 Mar 24
8-K
Departure of Directors or Certain Officers
22 Mar 24
S-8
Registration of securities for employees
11 Mar 24
8-K
CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update
11 Mar 24
10-K
2023 FY
Annual report
11 Mar 24
8-K
CytomX Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
7 Nov 23
10-Q
2023 Q3
Quarterly report
7 Nov 23
EFFECT
Notice of effectiveness
28 Aug 23
Transcripts
CTMX
Earnings call transcript
2023 Q4
11 Mar 24
CTMX
Earnings call transcript
2023 Q3
7 Nov 23
CTMX
Earnings call transcript
2023 Q2
8 Aug 23
CTMX
Earnings call transcript
2023 Q1
9 May 23
CTMX
Earnings call transcript
2022 Q4
27 Mar 23
CTMX
Earnings call transcript
2022 Q3
9 Nov 22
CTMX
Earnings call transcript
2022 Q2
6 Aug 22
CTMX
Earnings call transcript
2022 Q1
7 May 22
CTMX
Earnings call transcript
2021 Q4
2 Mar 22
CTMX
Earnings call transcript
2021 Q3
7 Nov 21
Latest ownership filings
4
Sean A. McCarthy
28 Mar 24
4
Zhen Su
22 Mar 24
3
Zhen Su
22 Mar 24
4
LLOYD A ROWLAND
21 Mar 24
4
Sean A. McCarthy
21 Mar 24
4
Christopher Ogden
21 Mar 24
4
MARCIA BELVIN
21 Mar 24
4
Jeffrey B Landau
21 Mar 24
SC 13G/A
TANG CAPITAL PARTNERS LP
14 Feb 24
SC 13G/A
BIOTECHNOLOGY VALUE FUND L P
14 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 26.94 mm | 26.94 mm | 26.94 mm | 26.94 mm | 26.94 mm | 26.94 mm |
Cash burn (monthly) | 10.50 mm | 5.75 mm | (no burn) | 1.06 mm | 6.08 mm | 2.96 mm |
Cash used (since last report) | 70.07 mm | 38.36 mm | n/a | 7.06 mm | 40.56 mm | 19.71 mm |
Cash remaining | -43.13 mm | -11.42 mm | n/a | 19.88 mm | -13.62 mm | 7.23 mm |
Runway (months of cash) | -4.1 | -2.0 | n/a | 18.8 | -2.2 | 2.4 |
Institutional ownership, Q2 2023
68.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 69 |
Opened positions | 5 |
Closed positions | 12 |
Increased positions | 20 |
Reduced positions | 19 |
13F shares | Current |
---|---|
Total value | 52.10 bn |
Total shares | 46.67 mm |
Total puts | 10.60 k |
Total calls | 35.10 k |
Total put/call ratio | 0.3 |
Largest owners | Shares | Value |
---|---|---|
Tang Capital Management | 6.60 mm | $11.35 bn |
Biotechnology Value Fund L P | 6.60 mm | $9.56 mm |
BVF | 6.60 mm | $11.34 bn |
Vanguard | 4.90 mm | $8.43 bn |
Tang Capital Partners | 3.51 mm | $0.00 |
Acadian Asset Management | 2.65 mm | $4.56 mm |
Lightstone Ventures II | 2.44 mm | $0.00 |
Jacobs Levy Equity Management | 1.62 mm | $2.79 bn |
Laurion Capital Management | 1.19 mm | $2.04 bn |
BLK Blackrock | 1.15 mm | $1.97 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
26 Mar 24 | McCarthy Sean A. | Common Stock | Option exercise | Acquire M | No | No | 1.5749 | 109,768 | 172.87 k | 634,249 |
26 Mar 24 | McCarthy Sean A. | Stock Option Common Stock | Option exercise | Dispose M | No | No | 1.5749 | 109,768 | 172.87 k | 0 |
20 Mar 24 | Zhen Su | Stock Option Common Stock | Grant | Acquire A | No | No | 2.27 | 76,000 | 172.52 k | 76,000 |
19 Mar 24 | Jeffrey B Landau | Common Stock | Sell | Dispose S | No | No | 2.0855 | 6,562 | 13.69 k | 110,060 |
19 Mar 24 | McCarthy Sean A. | Common Stock | Sell | Dispose S | No | No | 2.0855 | 20,223 | 42.18 k | 524,481 |
News
12 Health Care Stocks Moving In Wednesday's After-Market Session
10 Apr 24
Why Asana Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
12 Mar 24
BMO Capital Maintains Market Perform on CytomX Therapeutics, Lowers Price Target to $3.25
12 Mar 24
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Mar 24
Wedbush Reiterates Neutral on CytomX Therapeutics, Maintains $3 Price Target
12 Mar 24